Andre Nemesio and his team just named a brand new orchid bee Euglossa bazinga, after the catch phrase used by Sheldon Cooper on the television show, The Big Bang
Via The QI Elves
the benefits of curating the world's best content.
|history of medicine||1|
|metabolic bone disease||1|
Your new post is loading...
ABSTRACT: BACKGROUND: Divergent strategies have emerged for the management of severe asthma. One strategy utilises high and fixed doses of maintenance treatment, usually inhaled corticosteroid/longacting beta2-agonist (ICS/LABA), supplemented by a short-acting beta2-agonist (SABA) as needed. Alternatively, budesonide/formoterol is used as both maintenance and reliever therapy. The latter is superior to fixed-dose treatment in reducing severe exacerbations while achieving similar or better asthma control in other regards. Exacerbations may be reduced by the use of budesonide/formoterol as reliever medication during periods of unstable asthma. We examined the risk of a severe exacerbation in the period after a single day with high reliever use. METHODS: Episodes of high reliever use were quantified and exacerbations occurring post-index day with these episodes were examined post hoc in two double-blind studies comparing the efficacy and safety of budesonide/formoterol maintenance and reliever therapy (Symbicort SMARTTM, Turbuhaler(R)) 160/4.5 mug twice daily plus as needed with similar or higher maintenance doses of ICS/LABA plus SABA or formoterol. RESULTS: Budesonide/formoterol maintenance and reliever therapy significantly reduced the risk of episodes of high reliever use (>6 inhalations/day) vs. all alternative ICS/LABA regimens. With conventional fixed-dose treatment the need for exacerbation treatment within 21 days ranged from 6.0-10.1% of days post-index for all regimens compared with 2.5-3.4% of days with budesonide/formoterol maintenance and reliever therapy. CONCLUSIONS: Budesonide/formoterol maintenance and reliever therapy reduces the incidence of high reliever episodes and the exacerbation burden immediately following these episodes vs. alternative ICS/LABA plus SABA regimens at up to double the maintenance dose of ICS. Trial registration These studies do not have registration numbers as they were conducted before clinical trial registration was required.
Via David Lewis
Delete the scoop?
Are you sure you want to delete this scoop?